The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback